NEW YORK – Adaptive Biotechnologies said Monday after the close of the market that its second quarter revenues decreased 5 percent year over year, primarily due to a COVID-19 pandemic-related drop in its sequencing business.
For the three months ended June 30, 2020, the Seattle-based immune sequencing firm tallied revenues of $21.0 million compared to $22.1 million a year ago, ahead of analysts' average estimate of $18.8 million.